M3/M3v acute myeloid leukemia (AML M3/M3v)
Acute promyelocytic leukemia (APL)
Acute promyelocytic leukemia (APL) PML/RARA
2017-04-01 Marina Lafage  , Marina Lafage  
Affiliation
1.Department of Genetics, Aix-Marseille University, Marseille; [email protected] (ML), Service dHistologie-Embryologie-Cytogénétique, Unité de Cytogénétique Onco-Hématologique, Hôpital Universitaire Necker-Enfants Malades, 75015 Paris, France; [email protected].
2.MLL Münchner Leukümielabor GmbH, Max-Lebsche-Platz 31, 81377 München, Germany
Abstract
Review on Acute promyelocytic leukemia, with data on clinics and the genes involved.
Clinics and Pathology
Epidemiology
Account for approximatively. 5% of treatment related leukemias (t-AML); 5-22% of APL are t-APL, mostly after breast cancer treated by epirubicine or mitoxantrone (chemotherapy targeting topo 2 isomerase); short-delayed (median inferior to 3 years) ; favorable prognosis among t-AML: benefit from ATRA-ATO treatment thus avoiding anthracyclins (reviewed in Lo Coco F, 2013).
Clinics
Biological and clinical data favour a crucial role of the leukemic cells in the development of the coagulopathy which is a multifactorial event, involving DIC and primary hyperfibrinolysis (Mantha et al., 2016).
Cytology
Treatment
To be noted that some variant translocations, i.e. t(11;17) with ZBTB1/RARA fusion and der(17) with STAT5B/RARA fusion do not respond to ATRA and ATO therapy, consequently their prognosis is quite more pejorative.
Evolution
Prognosis
Cytogenetics
Cytogenetics morphological
Complex translocations involving one or more chromosomes in addition to 15 and 17 are found in 2-5% of cases with PML/RARA rearrangement.
Cytogenetically cryptic PML/RARA rearrangements are observed in 2-3% of APL cases.
Cases lacking PML/RARA rearrangement account for less than 2% M3/M3v AML cases and mainly involve RARA with partner genes different from PML (Grimwade D et al, Blood 2000).
Cytogenetics molecular
Furthermore as cytogenetic diagnosis is urgent, FISH analysis can be performed urgently in parallel with karyotype analysis, preferably on cultured and fixed cells.
Among cryptic rearrangements, they are mainly insertions:
Probes
Among these probes, some are less informative in case of cryptic insertions which accounts for approximately 5% of APL cases
The choice of informative probes has to take into account the probe maps and the critical fusion gene to be detected (PML/RARA rather than RARA/PML), thus covering 5PML and 3RARA. In order to obtain an optimal diagnosis (rapid and informative) multiple slides, each with a different type of probe can be hybridized. Furthermore, small insertions are easier to be detected on metaphases rather than on nuclei and the chromosomal location of the specific signals is very helpful for diagnosis. .
Other diagnosis tools are:
PML immunofluorescence leading to a specific microspeckled pattern in nuclei of PML/RARA positive cases, related to the disruption of PML nuclear bodies.
PML/RARA RT-PCR analysis, very specific and sensitive, mandatory at diagnosis.
Additional anomalies
Classically, ACA do not impact the prognosis, however the loss of one copy of TP53 gene generated by ider(17q) or del(17p) could have a prognostic value. Complex karyotype at diagnosis, defined as ≥ 2 anomalies in addition to t(15;17), could be associated too with a reduced overall survival (Poiré X et al., 2014).
Variants
The cases with variant translocation have initially been reported as having APL morphology. However, morphological differences exist. Clinically important is that APL variant with t(5;17)(q12;q12) NPM1/RARA, respond to ATRA, while M3/M3v AML with t(11;17)(q23;q12) ZBTB16/RARA or der(17) STAT5B/RARA do not respond to ATRA or ATO.
Genes Involved and Proteins
PML organises and is located in PML-nuclear bodies (PML-NBs) which are 0.2 to 1.0 m organelles, mainly located in the nucleus of many cell types. Their number varies from 5 to 30 per nucleus, according to the cell cycle and the differentiation stage. PML-NBs are actively involved in transcriptional regulation of a number of loci active in cell growth and differentiation. Proteins are stored or sequestered inside PML-NBs, until they are required. PML-NBs mediate protein modifications such as SUMOylation, acetylation, ubiquitination and phosphorylation (Bernardi and Pandolfi, 2007).
Result of the Chromosomal Anomaly
Description
PML/RARA is able to homodimerise via the coiled-coil domain of PML, forming a complex which binds to the DNA on RARE sites. It acts as a dominant-negative transcriptional repressor of both target and non-target genes of retinoic acid. The main consequence is the arrest of myeloid cells differentiation at the promyelocytic stage. To achieve the gene silencing process, PML/RARA recruits various nuclear receptors with co-repressor properties, out of which RXRα, polycomb complex or DAXX (ZHU et al.; 2007, Lo-Coco and Hasan, 2014).
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 32295268 | 2020 | Classic and Variants APLs, as Viewed from a Therapy Response. | 173 |
| 32182684 | 2020 | Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene. | 172 |
| 38503502 | 2024 | Acute Promyelocytic Leukemia, Retinoic Acid, and Arsenic: A Tale of Dualities. | 144 |
| 36145693 | 2022 | The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases. | 135 |
| 37388925 | 2023 | Biomolecular Condensates in Myeloid Leukemia: What Do They Tell Us? | 131 |
| 38061017 | 2023 | Proteogenomic analysis reveals cytoplasmic sequestration of RUNX1 by the acute myeloid leukemia-initiating CBFB::MYH11 oncofusion protein. | 112 |
| 21258047 | 2011 | Dynamics of epigenetic modifications in leukemia. | 104 |
| 23847762 | 2013 | PML, SUMOylation, and Senescence. | 100 |
| 41168841 | 2025 | Disease-specific epigenetic deregulation of enhancers, transposons, and polycomb targets in acute promyelocytic leukemia. | 95 |
| 34795215 | 2021 | Genetic fusions favor tumorigenesis through degron loss in oncogenes. | 95 |
| 38098967 | 2023 | Different Isoforms of PML-RARA Chimeric Protein in Patients with Acute Promyelocytic Leukemia: Survival Analysis per Demographic Characteristics, Clinicohematological Parameters, and Cytogenetic Findings. | 90 |
| 32215187 | 2020 | Acute promyelocytic leukemia (APL): a review of the literature. | 84 |
| 39766302 | 2024 | Rapid Detection of PML::RARA Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive Sampling. | 83 |
| 40773291 | 2025 | Overexpression of the signaling coordinator GAB2 can play an important role in acute myeloid leukemia progression. | 80 |
| 37655965 | 2023 | Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function. | 78 |
| 34193815 | 2021 | Acute promyelocytic leukemia current treatment algorithms. | 77 |
| 28017614 | 2017 | FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-Methyladenosine RNA Demethylase. | 74 |
| 32024232 | 2020 | Advances in Pediatric Acute Promyelocytic Leukemia. | 73 |
| 28794865 | 2017 | Recent advances in acute promyelocytic leukaemia. | 71 |
| 29795382 | 2018 | Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia. | 68 |
| 31431473 | 2019 | A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells. | 67 |
| 25750172 | 2015 | PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): from molecular mechanism to human AML. | 66 |
| 21059853 | 2010 | Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. | 65 |
| 24449212 | 2014 | Immune evasion by oncogenic proteins of acute myeloid leukemia. | 61 |
| 42663568 | 2026 | PML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization. | 60 |
| 26997274 | 2016 | NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia. | 56 |
| 37593318 | 2023 | Therapy-Related Acute Promyelocytic Leukemia: A Case Report and a Review of Literature. | 53 |
| 26595813 | 2016 | PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia. | 51 |
| 41440764 | 2025 | Acute Promyelocytic Leukemia: Pathophysiology, Diagnosis and Clinical Management. | 48 |
| 29772692 | 2018 | Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer. | 45 |
| 38304177 | 2024 | Acute promyelocytic leukemia with PML/RARA (bcr1, bcr2 and bcr3) transcripts in a pediatric patient. | 41 |
| 40421449 | 2025 | What Is Acute Myeloid Leukemia? | 37 |
| 35692786 | 2022 | Case Report: Extramedullary Acute Promyelocytic Leukemia: An Unusual Case and Mini-Review of the Literature. | 34 |
| 33257864 | 2021 | Readfish enables targeted nanopore sequencing of gigabase-sized genomes. | 33 |
| 39807666 | 2024 | Predictive modelling of acute Promyelocytic leukaemia resistance to retinoic acid therapy. | 31 |
| 33614484 | 2020 | Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia. | 31 |
| 28101221 | 2016 | A complex translocation (3;17;15) in acute promyelocytic leukemia confirmed by fluorescence in situ hybridization. | 31 |
| 38921185 | 2024 | Three-Way Translocation t(12;15;17) (p13;q24;q21) Found in Acute Promyelocytic Leukemia with Basophilic Differentiation. | 26 |
| 36672788 | 2022 | Acute Promyelocytic Leukemia with Rare Genetic Aberrations: A Report of Three Cases. | 26 |
| 41718414 | 2026 | Primary Indolent Acute Promyelocytic Leukemia. | 22 |
| 37685882 | 2023 | Cytogenetically Cryptic Acute Promyelocytic Leukemia: A Diagnostic Challenge. | 20 |
| 34668451 | 2022 | Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. | 19 |
| 39469370 | 2024 | Cytogenetic and Molecular Characteristics in Adult Hispanic Acute Myeloid Leukemia Patients From Puerto Rico. | 15 |
| 34673934 | 2022 | A novel NUP98-JADE2 fusion in a patient with acute myeloid leukemia resembling acute promyelocytic leukemia. | 15 |
| 28028657 | 2017 | PML-RARA mutations confer varying arsenic trioxide resistance. | 14 |
| 36465368 | 2022 | Case report: A rare case of TBL1XR1-RARB positive acute promyelocytic leukemia in child and review of the literature. | 13 |
| 41377785 | 2025 | Coexistence of Philadelphia Chromosome in Acute Promyelocytic Leukaemia: Two Rare Cases, with A Literature Review. | 11 |
| 34230915 | 2021 | PML/RARA destabilization by hyperthermia: a new model for oncogenic fusion protein degradation? | 10 |
| 33650061 | 2022 | The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients. | 10 |
| 38800206 | 2024 | Double Emergency: A Case of Concurrent Heparin-Induced Thrombocytopenia and Acute Promyelocytic Leukemia. | 10 |
| 35572917 | 2022 | Cytogenetically cryptic PML::RARA fusion in acute promyelocytic leukemia: Testing strategies in the modern era. | 10 |
| 38979565 | 2024 | Identification of a Novel MAPK1::BCR Fusion Gene/t(9;22) (q34;q11) in a Case of Acute Promyelocytic Leukemia. | 10 |
| 29245895 | 2017 | Progress and criticalities in the management of acute promyelocytic leukemia. | 7 |
| 37766564 | 2023 | Acute promyelocytic leukemia masquerading as myeloid maturation arrest- A Case report. | 7 |
| 31555723 | 2019 | Educational Case: Acute Promyelocytic Leukemia With PML-RARA. | 6 |
| 39397152 | 2025 | Therapy-Related Acute Promyelocytic Leukemia: Case Series and Current Insights. | 5 |
| 32185069 | 2020 | Acute promyelocytic leukemia presenting with atypical basophils. | 2 |
| 39017850 | 2024 | Function of PML-RARA in Acute Promyelocytic Leukemia. | 0 |
| 29083825 | 2023 | Acute Promyelocytic Leukemia (Archived). | 0 |
| 35854096 | 2022 | A novel RARA-SNX15 fusion in PML-RARA-positive acute promyelocytic leukemia with t(11;17;15)(q13;q21.2;q24.1). | 0 |
| 30536958 | 2019 | PML/RARA inhibits expression of HSP90 and its target AKT. | 0 |
| 30305503 | 2018 | [State-of-the-art treatment of acute promyelocytic leukemia]. | 0 |
| 35882408 | 2022 | MicroRNA-125b Accelerates and Promotes PML-RARa-driven Murine Acute Promyelocytic Leukemia. | 0 |
| 31281149 | 2019 | [Genetic abnormalities in AML]. | 0 |
| 37598913 | 2023 | PML/RARa leukemia induced murine model for immunotherapy evaluation. | 0 |
| 19215983 | 2009 | Aleukemic bcr-abl positive granulocytic sarcoma. | 0 |
| 32473106 | 2020 | Genotypic and Phenotypic Characteristics of Acute Promyelocytic Leukemia Translocation Variants. | 0 |
| 33983418 | 2021 | bcr3 PML-RARA: short fusion, small blasts! | 0 |
| 29136503 | 2017 | Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure. | 0 |
| 33162510 | 2020 | [Clinical significance of MRD in AML]. | 0 |
| 38303649 | 2024 | High-Fat Diet Induced PPARδ Promotes Self-renewal of Preleukemic Progenitors in Development of Acute Promyelocytic Leukemia. | 0 |
| 24907017 | 2014 | Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia? | 0 |
| 28735486 | 2017 | Detection and Quantification of Acute Myeloid Leukemia-Associated Fusion Transcripts. | 0 |
| 37726492 | 2023 | miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia. | 0 |
| 36112505 | 2022 | How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy. | 0 |
| 35963522 | 2022 | Fusion Gene Detection and Quantification by Asymmetric Capture Sequencing (aCAP-Seq). | 0 |
| 34405393 | 2021 | PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study. | 0 |
| 34725711 | 2022 | Acute Promyelocytic Leukemia with a BCR-ABL1 Rearrangement in a Minor Clone. | 0 |
| 34310740 | 2021 | RBCK1-TRIB3 decelerated the progression of acute promyelocytic leukemia. | 0 |
| 1337847 | 1992 | RARA and PML genes in acute promyelocytic leukemia. | 0 |
| 30421475 | 2019 | Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia. | 0 |
| 38153216 | 2024 | Identification of concurrent STAT3::RARA and RARA::STAT5b fusions in a variant APL case. | 0 |
| 17134965 | 2006 | Gene expression regulation and cancer. | 0 |
| 26374632 | 2016 | PML-RARa modulates the vascular signature of extracellular vesicles released by acute promyelocytic leukemia cells. | 0 |
| 21078537 | 2011 | Independent prognostic variables in acute myeloid leukaemia. | 0 |
| 24720386 | 2014 | RARA fusion genes in acute promyelocytic leukemia: a review. | 0 |
| 32016577 | 2020 | Chemogenomics analysis of drug targets for the treatment of acute promyelocytic leukemia. | 0 |
| 28025581 | 2017 | PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias. | 0 |
| 22056243 | 2012 | Curing APL through PML/RARA degradation by As2O3. | 0 |
| 35544458 | 2022 | A short report of novel RARG-HNRNPM fusion gene in resembling acute promyelocytic leukemia. | 0 |
| 25530565 | 2015 | Correlation between FLT3-ITD status and clinical, cellular and molecular profiles in promyelocytic acute leukemias. | 0 |
| 36476791 | 2022 | [Diagnostic efficacy of WT1 expression in asymptomatic acute promyelocytic leukemia]. | 0 |
| 33428799 | 2021 | Identification of a novel TNRC18-RARA fusion in acute promyelocytic leukemia lacking t(15;17)(q24;q12)/PML-RARA. | 0 |
| 19808868 | 2009 | Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. | 0 |
| 38294534 | 2024 | Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia. | 0 |
| 20805746 | 2010 | Assessment of minimal residual disease in acute myeloid leukemia. | 0 |
| 42660706 | 2026 | Advances in differentiation syndrome in acute promyelocytic leukemia: From mechanisms to management. | 0 |
| 33851647 | 2021 | Cytogenetics and FISH negative cryptic acute promyelocytic leukemia with CD56 expression. | 0 |
| 24596215 | 2014 | PML nuclear bodies mediate the therapeutic response of APL cells. | 0 |
| 42770952 | 2026 | Correction: PML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization. | 0 |
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 27069254 | 2016 | The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. | Arber DA et al |
| 17928811 | 2007 | Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. | Bernardi R et al |
| 24907017 | 2014 | Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia? | Grimwade D et al |
| 28322237 | 2017 | Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. | Kayser S et al |
| 24907012 | 2014 | Understanding the molecular pathogenesis of acute promyelocytic leukemia. | Lo-Coco F et al |
| 24981688 | 2014 | Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. | Lucena-Araujo AR et al |
| 26760586 | 2016 | What's new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia? | Mantha S et al |
| 27400939 | 2017 | Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. | Platzbecker U et al |
| 24160850 | 2014 | Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. | Poiré X et al |
| 12357344 | 2002 | Variations on a theme: the alternate translocations in APL. | Redner RL et al |
| 18812465 | 2009 | Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. | Sanz MA et al |
| 26920716 | 2016 | Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. | Testa U et al |
| 18299451 | 2008 | Acute promyelocytic leukemia: from highly fatal to highly curable. | Wang ZY et al |
| 17613434 | 2007 | RXR is an essential component of the oncogenic PML/RARA complex in vivo. | Zhu J et al |
Summary
Note
FAB criteria AML M3v
Immunophenotype
WHO classification (2008, updated 2016)
Citation
Marina Lafage ; Marina Lafage
M3/M3v acute myeloid leukemia (AML M3/M3v)
Acute promyelocytic leukemia (APL)
Acute promyelocytic leukemia (APL) PML/RARA
Atlas Genet Cytogenet Oncol Haematol. 2017-04-01
Historical Card
2006-01-01 M3/M3v acute myeloid leukemia (AML M3/M3v)
Acute promyelocytic leukemia (APL)
Acute promyelocytic leukemia (APL) PML/RARA by Claudia Schoch 
Affiliation
